Skip to content
DataLookout
Menu

Med-SBMANCT06862596

Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy

StatusActive, Not Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Enrollment closed, study ongoing
    • Secondary endpoints: details revised at 3 of 8 entries
    • Site details revised at 5 of 5 sites
  2. Minor Start date: Feb 26, 2025 to Feb 28, 2025
    • Site contacts updated at 1 of 5 sites
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score
Timeframe: at 4weeks

Secondary (8)

ALSFRS-R Score
Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS) score
Grip strength
Tongue pressure
Timed walk test (4.6 meters)
Show 3 moreShow less
6-minute walk test
Respiratory function test (Forced Vital Capacity (FVC))
Respiratory function test (Peak Expiratory Flow (PEF))

Arms and interventions

Mexiletine groupActive comparator
Placebo groupPlacebo comparator

Drugs: Mexiletine hydrochloride

Other: Placebo

Sites

5 sites in 1 country